Prevent an increase in the proportion of macrolide antibiotic-resistant Campylobacter infections — FS‑06 Data Methodology and Measurement

About the National Data

Data

Baseline: 2.5 percent of domestically-acquired Campylobacter jejuni infections in humans were resistant to macrolides in 2014-16

Target: 2.5 percent

Numerator
Number of domestically-acquired Campylobacter jejuni infections in humans resistant to macrolides.
Denominator
Number of domestically-acquired Campylobacter jejuni infections in humans tested for resistance to macrolides.
Target-setting method

Maintain the baseline

Target-setting method details
N/A
Target-setting method justification
Maintaining the baseline is the preferred target because, by reducing the overall incidence of infections and limiting the prevalence of resistance (maintaining the current level), a reduction in the incidence of antimicrobial resistant infections can be achieved.

Methodology

Methodology notes

Public health laboratories in 10 FoodNet sites forward a frequency-based sample of Campylobacter isolates that they receive from participating clinical/reference laboratories to NARMS at CDC. CDC scientists test isolates for susceptibility to macrolides and other drug classes using a broth microdilution method and interpret results using criteria from the Clinical and Laboratory Standards Institute (CLSI) when available. Domestically-acquired infections (i.e., no international travel in the 7 days before illness onset) will be identified using travel information available from FoodNet.

History

Comparable HP2020 objective
Modified, which includes core objectives that are continuing from Healthy People 2020 but underwent a change in measurement.
Changes between HP2020 and HP2030
This objective differs from Healthy People 2020 objective FS-3.6 in that objective FS-3.6 tracked Campylobacter jejuni infections that were resistant to erythomycin, while this objective tracks domestically-acquired Camplyobacter jejuni infections that are resistant to macrolide antibiotics.